GeneDx Holdings (WGS) revenue breakdown
By segment, GeneDx is the largest at 99% of fiscal 2025 revenue, growing 51% a year over 3 years.
By product, Patients with third-party insurance is the largest at 81% of fiscal 2025 revenue; Institutional customers grew fastest, 22% a year over 6 years.
Revenue by segment
Fiscal years, as GeneDx Holdings reports them in its 10-K filings; fiscal 2025 total $428M.
| Segments | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|
| GeneDx | $122M | $194M | $302M | $423M | 99% |
| Other | $112M | $8M | $3M | $4M | 1% |
Revenue by product
Fiscal years, as GeneDx Holdings reports them in its 10-K filings; fiscal 2025 total $428M.
| Products | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|
| Patients with third-party insurance | $170M | $138M | $170M | $174M | $134M | $235M | $345M | 81% |
| Institutional customers | $21M | $35M | $32M | $46M | $59M | $65M | $70M | 16% |
| Other revenue | $5M | $4M | $7M | $7M | $7M | $3M | $11M | 3% |
| Self-pay patients | $1M | $2M | $4M | $8M | $2M | $2M | $1M | 0% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for WGS.
Open WGS in InvestinglyQuestions
Where does GeneDx Holdings make its money?
In fiscal 2025, by segment: GeneDx $423M, Other $4M.
From GeneDx Holdings's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.